中药联合昆仙胶囊、黄葵胶囊治疗顽固性皮肤型过敏性紫癜的疗效观察

    Treatment of refractory Henoch-Schonlein purpura with Kunxian capsule and Huangkui capsule

      摘要
    • 摘要:
      目的  探讨中药联合昆仙胶囊、黄葵胶囊治疗顽固性皮肤型过敏性紫癜的疗效及其安全性分析。
      方法  收集2018年9月至2022年3月河南中医药大学第一附属医院儿科门诊就诊的顽固性皮肤型过敏性紫癜患者，采用随机数字表法分为A、B、C 3组，A组为单纯中药治疗、B组在中药治疗的基础上加用昆仙胶囊、C组在中药治疗的基础上加用黄葵胶囊，随访记录3组患者用药2、4、6、8周时紫癜消退情况、反复次数、疗程及不良反应。
      结果  共纳入顽固性皮肤型过敏性紫癜患者87例，其中A组30例、B组29例、C组28例。B组治疗2周时疗效明显优于A组和C组，差异具有统计学意义（P＜0.05）；B组和C组治疗4周时疗效均优于A组，且B组疗效优于C组，差异具有统计学意义（P＜0.05）；B组和C组治疗6、8周时疗效均优于A组，差异具有统计学意义（P＜0.05），B组与C组疗效差异无统计学意义（P＞0.05）；B组和C组在用药2、4、6、8周时皮疹反复次数均少于A组，差异具有统计学意义（P＜0.05）；B组在用药2、4、6周时皮疹反复次数均少于C组，差异具有统计学意义（P＜0.05），治疗8周时，B组与C组皮疹反复次数比较差异无统计学意义（P＞0.05）；B组和C组疗程均少于A组，差异具有统计学意义（P＜0.05），B组、C组组间疗程比较差异无统计学意义（P＞0.05）；A组、B组、C组患者不良事件发生率分别为6.67%、13.79%、10.71%，差异无统计学意义（P＞0.05）。
      结论 中药联合昆仙胶囊、黄葵胶囊均能促进顽固性皮肤型过敏性紫癜皮疹的消退、减少皮疹反复次数，以中药联合昆仙胶囊效果更佳，起效更快，且二者均无明显不良反应。

       

      Abstract:
      Objective  To explore the curative effect and safety of traditional Chinese medicine (TCM) plus Kunxian capsule and Huangkui capsule for refractory Henoch-Schonlein purpura (HSP).
      Methods  From September 2018 to March 2022, 87 patients with refractory HSP were randomized into three groups of A (n=30), B (n=29) and C (n=28) : group A received TCM, group B Kunxian capsule on the basis of TCM and group C Huangkui capsule on the basis of TCM. Subsiding status, recurrent rate, dosing course and adverse events were recorded at Week 2/4/6/8 after medication.
      Results  After 2-week treatment, the curative effect of group B was significantly better than that of group A/C (P<0.05). After 4-week treatment, the curative effect of group B/C was better than that of group A. And the curative effect of group B was better than that of group C with statistical significance (P<0.05). After 6/8-week treatment, the curative effect of group B/C was better than that of group A and the difference was statistically significant (P<0.05), However, no statistical difference existed between groups B and C (P>0.05). The recurrent rate of rash in group B/C was less than those in group A at Week 2/4/6/8 and the difference was statistically significant (P<0.05). The recurrent rate of rash in group B was less than that in group C at Week 2/4/6 and the difference was statistically significant (P<0.05). However, the recurrent rate of rash in group B/C at Week 8 was not statistically significant (P>0.05). The dosing course was shorter in group B/C than that in group A and the difference was statistically significant (P<0.05). However, no statistical difference existed between groups B and C (P>0.05). The incidence of adverse events in groups A, B and C were 6.67%, 13.79% and 10.71% respectively with no statistical significance (P>0.05).
      Conclusion  TCM plus Kunxian capsule and Huangkui capsule may promote the regression of rash and lower its recurrent rate in refractory HSP. And TCM plus Kunxian capsule has a better efficacy with a quicker onset and both capsules have no obvious adverse reactions.

       

      • HTML全文
      • 参考文献(33)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回